Hims & Hers Faces FTC Lawsuit: Implications for Telehealth Investors
Hims & Hers faces regulatory scrutiny, prompting a closer look at its telehealth business model and market sentiment.
BioMarin's Strategic Acquisition: What It Means for Investors
BioMarin's $275M acquisition of Alesta Therapeutics could enhance its rare disease focus and shareholder value.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
30-Year Treasury Yield at 19-Year High: What It Means for US and Canadian Markets
The 30-year US Treasury yield has hit a 19-year high, reshaping market landscapes and investor strategies.
Curaleaf's Hostile Bid for Aurora Cannabis: Implications for North American Cannabis Investors
Curaleaf's $4/share bid for Aurora Cannabis signals major changes in the cannabis sector, impacting investors across the…
Amylyx Pharmaceuticals' Avexitide Phase 3 Success: What Investors Need to Know
Amylyx's Phase 3 success with avexitide shows promise for investors, especially amid past setbacks.
Nvidia's Strategic Move: Financing OpenAI's Data Center in Ohio
Nvidia's financing of OpenAI's data center marks a pivotal moment in AI infrastructure and investor sentiment.
Raytheon's $22.9 Billion Contract: A Game Changer for Defense Investors
Raytheon's $22.9 billion contract signals a shift in defense spending amidst rising geopolitical tensions.
S&P 500's Record Surge: What Lies Beneath the Earnings Rally?
The S&P 500 hits record highs, but analysts raise questions about the sustainability of this earnings-driven rally.
TTM Technologies Acquires Epiq Solutions: A Strategic Move in Defense Electronics
TTM Technologies' $1.1 billion acquisition of Epiq Solutions signals a strong move in the defense electronics sector.
Analyzing the Fulcrum and Slate Merger: A New Era for Migraine Therapies
Fulcrum Therapeutics and Slate Medicines merge to create a powerhouse in migraine therapies, signaling a pivotal shift i…
Iovance Biotherapeutics' Q2 Earnings: Strong Momentum in Oncology
Iovance Biotherapeutics showcases promising developments in oncology, highlighted by a key FDA designation and strong cl…